{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:05:29Z","timestamp":1793480729352,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministry of Education University and Research","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1053\/j.semnuclmed.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:52:19Z","timestamp":1746312739000},"page":"565-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["PET\/CT in Movement Disorders: Update"],"prefix":"10.1053","volume":"55","author":[{"given":"Matilde","family":"Nerattini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Maria","family":"Abenavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-6559","authenticated-orcid":false,"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0001","article-title":"FDG-PET combined with learning vector quantization allows classificati on of neurodegenerative diseases and reveals the trajectory of idiopat hic REM sleep behavior disorder","volume":"225","author":"Rick","year":"2022","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1142\/S0129065719500102","article-title":"Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson's Disease in 3D Nuclear Imaging Data","volume":"29","author":"Manzanera","year":"2019","journal-title":"Int J Neural Syst"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103475","article-title":"Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in \u03b1-synucleinopathies","volume":"39","author":"Carli","year":"2023","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0004","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fnins.2019.00396","article-title":"Use of Overlapping Group LASSO Sparse Deep Belief Network to Discriminate Parkinson's Disease and Normal Control","volume":"13","author":"Shen","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.nicl.2018.08.006","article-title":"FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease","volume":"20","author":"Matthews","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fnagi.2020.00125","article-title":"Brain Functional and Structural Signatures in Parkinson's Disease","volume":"12","author":"Jie","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0007","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/brain\/awaa019","article-title":"Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction","volume":"143","author":"Ruppert","year":"2020","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fncom.2024.1328699","article-title":"Random forest analysis of midbrain hypometabolism using [18F]-FDG PET identifies Parkinson's disease at the subject-level","volume":"18","author":"Ruppert-Junck","year":"2024","journal-title":"Frontiers in Computational Neuroscience"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105848","article-title":"Atypical brain FDG-PET patterns increase the risk of long-term cognitive and motor progression in Parkinson's disease","volume":"115","author":"Imarisio","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.14336\/AD.2018.0814","article-title":"The Metabolic Activity of Caudate and Prefrontal Cortex Negatively Correlates with the Severity of Idiopathic Parkinson's Disease","volume":"10","author":"Chu","year":"2019","journal-title":"Aging Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0011","doi-asserted-by":"crossref","first-page":"773","DOI":"10.21037\/atm.2019.11.26","article-title":"Use of radiomic features and support vector machine to distinguish Parkinson's disease cases from normal controls","volume":"7","author":"Wu","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0012","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41598-022-06663-0","article-title":"A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism","volume":"12","author":"Papathoma","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0013","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.13269","article-title":"Evaluation of an optimized [(18) F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders","volume":"24","author":"Caminiti","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0014","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1007\/s10072-022-06166-w","article-title":"FDG PET in the differential diagnosis of degenerative parkinsonian dis orders: usefulness of voxel-based analysis in clinical practice","volume":"43","author":"Arnone","year":"2022","journal-title":"Neurological Sciences"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2022.100399","article-title":"Utility of 18F FDG-PET in Parkinsonism in an African population","volume":"27","author":"Amod","year":"2022","journal-title":"eNeurologicalSci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s43657-022-00079-6","article-title":"Adjustment for the Age- and Gender-Related Metabolic Changes Improves the Differential Diagnosis of Parkinsonism","volume":"3","author":"Lu","year":"2023","journal-title":"Phenomics"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0017","first-page":"4256","article-title":"Altered brain metabolic connectivity at multiscale level in early","volume":"7","author":"Sala","year":"2017","journal-title":"Parkinson's disease. Sci Rep"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0018","first-page":"e305","article-title":"The reconfiguration pattern of individual brain metabolic connectome f or Parkinson's disease identification","volume":"4","author":"Weikai","year":"2020","journal-title":"MedComm"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0019","article-title":"Spectral guided sparse inverse covariance estimation of metabolic networks in","volume":"226","author":"Spetsieris","year":"2021","journal-title":"Parkinson's disease"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0020","doi-asserted-by":"crossref","first-page":"bhae355","DOI":"10.1093\/cercor\/bhae355","article-title":"Metabolic network connectivity disturbances in Parkinson's disease: a novel imaging biomarker","volume":"34","author":"Chen","year":"2024","journal-title":"Cerebral Cortex"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103488","article-title":"Parkinson's disease progression: Increasing expression of an invariant common core subnetwork","volume":"39","author":"Spetsieris","year":"2023","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/hbm.70026","article-title":"Individual-specific metabolic network based on (18)F-FDG PET revealing multi-level aberrant metabolisms in Parkinson's disease","volume":"45","author":"Lu","year":"2024","journal-title":"Hum Brain Mapp"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54695-z","article-title":"Longitudinal network changes and phenoconversion risk in isolated REM sleep behavior disorder","volume":"15","author":"Tang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0024","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/hbm.25393","article-title":"The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach","volume":"42","author":"Ruppert","year":"2021","journal-title":"Hum Brain Mapp"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.parkreldis.2020.10.036","article-title":"Impaired metabolic brain networks associated with neurotransmission sy stems in the \u03b1-synuclein spectrum","volume":"81","author":"Carli","year":"2020","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0026","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.nicl.2017.03.011","article-title":"Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease","volume":"14","author":"Caminiti","year":"2017","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0027","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnins.2019.00299","article-title":"Quantitative Research of (11)C-CFT and (18)F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software","volume":"13","author":"Sun","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0028","article-title":"Positron emission tomography\/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-\u03b2-carbomethoxy-3-\u03b2-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0029","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s00415-024-12477-z","article-title":"Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease","volume":"271","author":"Yoo","year":"2024","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107086","article-title":"Monoaminergic degeneration, cognition, and autonomic symptom trajectory in early Parkinson's disease","volume":"127","author":"Kim","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105668","article-title":"Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes","volume":"167","author":"Boccalini","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94040-8","article-title":"Diagnostic accuracy of dual-phase (18)F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0033","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2967\/jnumed.120.257345","article-title":"Dynamic (18)F-FPCIT PET: Quantification of Parkinson's disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session","volume":"62","author":"Peng","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213392","article-title":"Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease","volume":"104","author":"Yoo","year":"2025","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106024","article-title":"Patterns of regional cerebral hypoperfusion in early Parkinson's disease: Clinical implications","volume":"121","author":"Chung","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0036","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-022-00930-x","article-title":"[(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism","volume":"12","author":"Marner","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0037","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00259-019-04587-y","article-title":"Quantification and discriminative power of (18)F-FE-PE2I PET in patients with Parkinson's disease","volume":"47","author":"Delva","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0038","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","article-title":"Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison","volume":"8","author":"Jakobson Mo","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13550-023-00974-7","article-title":"[(18)F]FE-PE2I DAT correlates with Parkinson's disease duration, stage, and rigidity\/bradykinesia scores: a PET radioligand validation study","volume":"13","author":"Kerstens","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"(11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0041","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/mds.29148","article-title":"Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease","volume":"37","author":"Delva","year":"2022","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0042","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0271678X20958755","article-title":"Simplified quantification of [(18)F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium","volume":"41","author":"Brumberg","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0043","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13550-020-00676-4","article-title":"Reliability of dopamine transporter PET measurements with [(18)F]FE-PE2I in patients with Parkinson's disease","volume":"10","author":"Kerstens","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0044","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3174\/ajnr.A8207","article-title":"Optimization of [18 F]-FDOPA Brain PET Acquisition Times for Assessment of Parkinsonism in the Clinical Setting","volume":"45","author":"Keir","year":"2024","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.nbd.2019.01.003","article-title":"Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease","volume":"24","author":"Glaab","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0046","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/imj.16615","article-title":"Clinical utility of (18)F-fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience","volume":"55","author":"Yeow","year":"2025","journal-title":"Intern Med J"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0047","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/jcm13030875","article-title":"Dopamine Synthesis in the Nigrostriatal Dopaminergic System in Patient s at Risk of Developing Parkinson's Disease at the Prodromal Stage","volume":"13","author":"Blokhin","year":"2024","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0048","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023060","article-title":"Clinical impact of dual-tracer FDOPA and FDG PET\/CT for the evaluation of patients with parkinsonian syndromes","volume":"99","author":"Emsen","year":"2020","journal-title":"Medicine"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0049","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/brainsci14090930","article-title":"Brain Evaluation by Dual PET\/CT with [18 F] FDOPA and [18 F] FDG in Differential Diagnosis of Parkinsonian Syndromes","volume":"14","author":"Sinisterra Solis","year":"2024","journal-title":"Brain Sci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41531-022-00341-8","article-title":"Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease","volume":"8","author":"Steidel","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0051","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/brain\/awaa019","article-title":"Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction","volume":"143","author":"Ruppert","year":"2020","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0052","article-title":"Diagnostic value of striatal (18)F-FP-DTBZ PET in Parkinson's disease","volume":"14","author":"Liu","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105979","article-title":"(18)F-FP-DTBZ PET\/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease","volume":"120","author":"Huang","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0054","doi-asserted-by":"crossref","first-page":"e2314","DOI":"10.1212\/WNL.0000000000207748","article-title":"Using (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease","volume":"101","author":"Beauchamp","year":"2023","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.902169","article-title":"A Multi-Atlas-Based [18F]9-Fluoropropyl-(+)-Dihydrotetrabenazine Positron Emission Tomography Image Segmentation Method for Parkinson's Disease Quantification","volume":"14","author":"Pan","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0056","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41181-024-00301-y","article-title":"First-in-human study of D6-[(18)F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [(18)F]FP-(+)-DTBZ (AV-133)","volume":"9","author":"Zhao","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0057","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/mds.28632","article-title":"Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies","volume":"36","author":"Kaasinen","year":"2021","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2024.05.006","article-title":"Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson's and related diseases","volume":"112","author":"Endo","year":"2024","journal-title":"Neuron"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.06.004","article-title":"Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies","volume":"186","author":"Xiang","year":"2023","journal-title":"Cell"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108985","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","volume":"208","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0061","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/diagnostics13061029","article-title":"PET Imaging of Neuro-Inflammation with Tracers Targeting the Translocator Protein (TSPO), a Systematic Review: From Bench to Bedside","volume":"13","author":"Corica","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0062","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41531-024-00655-9","article-title":"Synaptic loss and its association with symptom severity in Parkinson's disease","volume":"10","author":"Holmes","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0063","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.25682","article-title":"Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging","volume":"87","author":"Matuskey","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0064","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/brain\/awae186","article-title":"Cholinergic deficiency in Parkinson's disease patients with visual hallucinations","volume":"147","author":"D'Angremont","year":"2024","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.31083\/j.jin2309178","article-title":"Topography of Cholinergic Nerve Terminal Vulnerability and Balance Self-Efficacy in Parkinson's Disease","volume":"23","author":"Barr","year":"2024","journal-title":"J Integr Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0066","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/brain\/awad420","article-title":"Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson's disease","volume":"147","author":"Crowley","year":"2024","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107229","article-title":"Regional cerebral cholinergic vesicular transporter correlates of visual contrast sensitivity in Parkinson's disease: Implications for visual and cognitive function","volume":"131","author":"Brown","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0068","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.24859","article-title":"Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies","volume":"81","author":"Pagano","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0069","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00259-020-04683-4","article-title":"High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort","volume":"47","author":"Fazio","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1827","article-title":"Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy","volume":"10","author":"Zhao","year":"2020","journal-title":"Brain Behav"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0071","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmp.2022.04.016","article-title":"Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy","volume":"98","author":"Tom\u0161e","year":"2022","journal-title":"Phys Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0072","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/diagnostics13010006","article-title":"Differences in Striatal Metabolism in [(18)F]FDG PET in Parkinson's Disease and Atypical Parkinsonism","volume":"13","author":"Seiffert","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0073","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-023-01025-x","article-title":"Diagnostic accuracy of cerebral [(18)F]FDG PET in atypical parkinsonism","volume":"13","author":"Houssein","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0074","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41531-020-00141-y","article-title":"Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy","volume":"6","author":"Brumberg","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0075","first-page":"1741","article-title":"Differential Diagnosis of Parkinsonism Based on Deep Metabolic Imaging Indices","volume":"63","author":"Wu","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0076","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1007\/s00259-021-05325-z","article-title":"Multivariate radiomics models based on (18)F-FDG hybrid PET\/MRI for distinguishing between Parkinson's disease and multiple system atrophy","volume":"48","author":"Hu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0077","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s00330-023-10003-9","article-title":"Identification of Parkinson's disease and multiple system atrophy using multimodal PET\/MRI radiomics","volume":"34","author":"Sun","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0078","doi-asserted-by":"crossref","first-page":"e1663","DOI":"10.1212\/WNL.0000000000011634","article-title":"Variability of FP-CIT PET Patterns Associated With Clinical Features of Multiple System Atrophy","volume":"96","author":"Lee","year":"2021","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0079","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1097\/RLU.0000000000005347","article-title":"Clinical Application of 18 F-THK5351 PET to Image Ongoing Astrogliosis in MSA-P and MSA-C","volume":"49","author":"Kondo","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.28295","article-title":"Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [(18) F]-MPPF PET Study","volume":"36","author":"Meyer","year":"2021","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0081","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0082","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jocn.2020.06.008","article-title":"Clinical, MRI and 18F-FDG-PET\/CT analysis of progressive supranuclear palsy","volume":"80","author":"Zhao","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0083","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00259-024-06954-w","article-title":"Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging","volume":"52","author":"Wang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0084","article-title":"Added value of FDG-PET for detection of progressive supranuclear palsy","volume":"96","author":"Buchert","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0085","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1007\/s00415-023-11824-w","article-title":"Brain FDG-PET correlates of saccadic disorders in early PSP","volume":"270","author":"Pin","year":"2023","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0086","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1007\/s00415-024-12350-z","article-title":"Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants","volume":"271","author":"Black","year":"2024","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0087","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ane.13653","article-title":"Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes","volume":"146","author":"Chen","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0088","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/mds.29769","article-title":"Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy","volume":"39","author":"Ma","year":"2024","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0089","doi-asserted-by":"crossref","first-page":"bhae355","DOI":"10.1093\/cercor\/bhae355","article-title":"Metabolic network connectivity disturbances in Parkinson's disease: a novel imaging biomarker","volume":"34","author":"Chen","year":"2024","journal-title":"Cereb Cortex"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0090","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00415-022-11556-3","article-title":"Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis","volume":"270","author":"Jin","year":"2023","journal-title":"J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2021.102850","article-title":"Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy","volume":"32","author":"Sintini","year":"2021","journal-title":"Neuroimage Clin"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0092","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0093","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0094","article-title":"Self-Reported REM Sleep Behavior Disorder in Patients With Progressive Supranuclear Palsy: Clinical and (18)F-Florzolotau PET Imaging Findings","volume":"104","author":"Li","year":"2025","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/mdc3.13885","article-title":"Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings","volume":"10","author":"Mena","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0096","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-022-06104-0","article-title":"(18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy","volume":"50","author":"Liu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0097","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/ana.25911","article-title":"Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy","volume":"88","author":"Malpetti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0098","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-022-05952-0","article-title":"Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [(18)F]PI-2620 PET\/MRI study","volume":"50","author":"Aghakhanyan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0099","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fnagi.2019.00249","article-title":"PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes","volume":"11","author":"Sch\u00f6necker","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/wjnm.WJNM_62_20","article-title":"((18)F)-Fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging assessment of hypometabolism patterns in clinical phenotypes of suspected corticobasal degeneration","volume":"20","author":"Franceschi","year":"2021","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0101","doi-asserted-by":"crossref","first-page":"e1121","DOI":"10.1212\/WNL.0000000000007038","article-title":"FDG-PET patterns associated with underlying pathology in corticobasal syndrome","volume":"92","author":"Pardini","year":"2019","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(02)00102-8","article-title":"Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration","volume":"199","author":"Hosaka","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0103","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1093\/brain\/awu256","article-title":"A disease-specific metabolic brain network associated with corticobasal degeneration","volume":"137","author":"Niethammer","year":"2014","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0104","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/ene.13729","article-title":"Cognitive reserve maps the core loci of neurodegeneration in corticobasal degeneration","volume":"25","author":"Isella","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0105","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/diagnostics12061402","article-title":"Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson's Disease Using Quantitative Indices of (18)F-FP-CIT PET\/CT","volume":"12","author":"Cheon","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0106","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.parkreldis.2022.04.015","article-title":"PET-based classification of corticobasal syndrome","volume":"98","author":"Nakano","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0107","article-title":"Imaging pathological tau in atypical parkinsonisms: A review","volume":"7","author":"Mena","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0108","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/mds.20040","article-title":"Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration","volume":"19","author":"Henkel","year":"2004","journal-title":"Mov Disord"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0109","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0110","first-page":"1591","article-title":"Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study","volume":"42","author":"Feigin","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0111","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","article-title":"Metabolic network as a progression biomarker of premanifest Huntington's disease","volume":"123","author":"Tang","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0112","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jnnp-2017-316633","article-title":"Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies","volume":"89","author":"Niccolini","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0113","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","article-title":"Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?","volume":"9","author":"Shin","year":"2013","journal-title":"J Clin Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0114","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington's disease","volume":"43","author":"Pagano","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0115","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0116","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0117","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2967\/jnumed.111.101543","article-title":"PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17","volume":"53","author":"Brockmann","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.irn.2018.09.011","article-title":"Neuroimaging Applications in Chronic Ataxias","volume":"143","author":"Mascalchi","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0119","first-page":"262","article-title":"In vivo imaging of synaptic loss in spinocerebellar ataxia type 3 with [18F]SDM-8 positron emission tomography","volume":"61","author":"Liao","year":"2020","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-023-00600-z","article-title":"Translational molecular imaging and drug development in Parkinson's disease","volume":"18","author":"Haider","year":"2023","journal-title":"Mol Neurodegener"},{"key":"10.1053\/j.semnuclmed.2025.03.007_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-024-00787-9","article-title":"Positron emission tomography tracers for synucleinopathies","volume":"20","author":"Xiang","year":"2025","journal-title":"Mol Neurodegener"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:59:01Z","timestamp":1762073941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001299825000364"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT in Movement Disorders: Update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}